| Literature DB >> 27885251 |
Yoshihiro Saito1, Joji Ishikawa1, Kazumasa Harada1.
Abstract
BACKGROUND Postprandial hypotension, induced by an absorption of glucose from intestine, could be treated by acarbose; however, it was unclear whether dipeptidyl peptidase-4 inhibitor reduced postprandial hypotension. CASE REPORT A 78-year-old woman who had experienced episodes of dizziness and hypotension after eating was admitted to our hospital. During 24-hour ambulatory blood pressure monitoring, there were repeated episodes of marked postprandial hypotension; i.e., a significant systolic blood pressure reduction within two hours after eating (from -58 to -64 mm Hg after meals). The patient was diagnosed with dementia with Lewy bodies. The patient exhibited postprandial hyperglycemia and hypotension after a 75 g oral glucose tolerance test. After the administration of 25 mg sitagliptin, the patient's postprandial and orthostatic hypotension was reduced remarkably. Moreover, her Mini-Mental State Examination score subsequently increased (from 22 to 25 points). CONCLUSIONS The dipeptidyl peptidase-4 inhibitor sitagliptin can delay postprandial increases in glucose levels and hypotensive episodes, as well as sympathetic nervous system abnormalities and orthostatic hypotension.Entities:
Keywords: Autonomic Nervous System Diseases; Hypotension; Hypotension, Orthostatic; Lewy Body Disease; Postprandial Period
Mesh:
Substances:
Year: 2016 PMID: 27885251 PMCID: PMC5127632 DOI: 10.12659/AJCR.900620
Source DB: PubMed Journal: Am J Case Rep ISSN: 1941-5923
Characteristics and blood examination of the patient.
| Age, 78, years |
| Gender, Female |
| Body height, 151 cm |
| Body weight, 54 kg |
| Body mass index, 23.7 kg/m2 |
| White blood cells, 5,680 (4,000–7,500)/μL |
| Hemoglobin, 12.7 (11.5–15.5) g/dL |
| Platelet, 14.5×103 (12.0–34.0×103)/μL |
| Fasting blood glucose, 125 (65–110), mg/dL |
| Hemoglobin A1c, 6.0 (4.6–6.2) % |
| Total bilirubin, 0.9 (0.2–1.0), mg/dL |
| Aspartate aminotransferase (AST), 18 (8–38) IU/L |
| Alanine aminotransferase (ALT), 11 (4–44) IU/L |
| Lactate dehydrogenase (LD), 159 (106–211) IU/L |
| Creatinine phosphokinase, 67 (14–180) IU/L |
| Blood urea nitrogen, 15.0 (10–25) mg/dL |
| Creatinine, 1.08 (0.60–1.00) mg/dL |
| Na, 142 (138–146) mEq/L |
| K, 4.5 (3.5–4.7), mEq/L |
| Cl, 105 (97–110) mEq/L |
| C-reactive protein, 0.12 (<0.31) mg/dL |
Data in the parenthesis shows normal values.
Figure 1.24-hour ambulatory blood pressure monitoring before the administration of sitagliptin. Ambulatory blood pressure monitoring was performed at 15-minute intervals for 24 hours.
Figure 2.Head-up tilt test results obtained before the administration of sitagliptin. Blood pressure was measured using an automatic cuff-oscillometric device at 5-minute intervals.
Changes in heart rate variability measures after standing-up.
| Baseline | ||||
| Systolic blood pressure, mmHg | 147 | 116 | 106 | 131 |
| Diastolic blood pressure, mmHg | 81 | 67 | 69 | 81 |
| Heart rate, bpm | 62 | 66 | 69 | 69 |
| High frequency (HF), Hz | 134.59 | 137.03 | 55.92 | 46.65 |
| Low frequency (LF), Hz | 124.57 | 111.52 | 57.01 | 63.06 |
| LF/HF ratio | 1.26 | 0.83 | 1.22 | 1.72 |
| After taking sitagliptin 25 mg just after waking up | ||||
| Systolic blood pressure, mmHg | 140 | 127 | 130 | 126 |
| Diastolic blood pressure, mmHg | 79 | 80 | 77 | 77 |
| Heart rate, bpm | 74 | 77 | 76 | 74 |
| High frequency (HF), Hz | 38.73 | 39.20 | 18.35 | 51.40 |
| Low frequency (LF), Hz | 30.28 | 41.11 | 27.53 | 99.77 |
| LF/HF ratio | 0.81 | 1.02 | 1.66 | 2.04 |
Figure 3.H/M ratio on MIBG scintigraphy before the administration of sitagliptin.
Figure 4.The patient’s DAT scans.
Changes in blood pressure, blood glucose, and insulin level after 75 g oral glucose ingestion or intravenous administration of 20% glucose 20 mL.
| Baseline | |||||
| 75 g oral glucose ingestion | |||||
| Systolic blood pressure, mm Hg | 162 | 116 | 119 | 129 | 130 |
| Diastolic blood pressure, mm Hg | 90 | 69 | 72 | 80 | 80 |
| Blood glucose, mg/dL | 100 | 208 | 240 | 285 | 274 |
| Insulin, μU/L | 4.4 | 19.2 | 25.8 | 36.3 | 58.5 |
| 20% glucose 20 mL intravenously | |||||
| Systolic blood pressure, mm Hg | 146 | 147 | 157 | 176 | 160 |
| Diastolic blood pressure, mm Hg | 85 | 88 | 91 | 97 | 96 |
| Blood glucose, mg/dl | 100 | 120 | 106 | 102 | 103 |
| Insulin, μU/l | 4.0 | 5.7 | 3.8 | 3.5 | 3.0 |
| After taking sitagliptin 25 mg just after waking | |||||
| 75 g oral glucose ingestion | |||||
| Systolic blood pressure, mm Hg | 190 | 148 | 155 | 137 | 144 |
| Diastolic blood pressure, mm Hg | 103 | 80 | 85 | 81 | 84 |
| Blood glucose, mg/dL | 100 | 157 | 144 | 170 | 186 |
| Insulin, μU/L | 4.5 | 20.7 | 13.7 | 18 | 23.8 |
Figure 5.24-hour ambulatory blood pressure monitoring after the administration of sitagliptin. Ambulatory blood pressure monitoring was performed at 15-minute intervals for 24 hours.
Figure 6.Head-up tilt test results obtained after the administration of sitagliptin. Blood pressure was measured using an automatic cuff-oscillometric device at 5-minute intervals.
Figure 7.H/M ratio on MIBG scintigraphy after the administration of sitagliptin.
Figure 8.24-hour ambulatory blood pressure monitoring, under the administration of sitagliptin, after one-year follow-up. Ambulatory blood pressure monitoring was performed at 30-minute intervals for 24 hours.